Caroline Godfrey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10489464/publications.pdf

Version: 2024-02-01

22 papers	2,281 citations	430442 18 h-index	676716 22 g-index
22 all docs	22 docs citations	22 times ranked	2911 citing authors

#	Article	IF	Citations
1	Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain, 2007, 130, 2725-2735.	3.7	385
2	Dystroglycanopathies: coming into focus. Current Opinion in Genetics and Development, 2011, 21, 278-285.	1.5	225
3	Delivery of therapeutic oligonucleotides with cell penetrating peptides. Advanced Drug Delivery Reviews, 2015, 87, 52-67.	6.6	217
4	Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Molecular Therapy - Nucleic Acids, 2012, 1, e38.	2.3	177
5	Brain involvement in muscular dystrophies with defective dystroglycan glycosylation. Annals of Neurology, 2008, 64, 573-582.	2.8	172
6	Fukutingene mutations in steroid-responsive limb girdle muscular dystrophy. Annals of Neurology, 2006, 60, 603-610.	2.8	140
7	Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy. Molecular Therapy - Nucleic Acids, 2012, 1, e39.	2.3	127
8	Delivery is key: lessons learnt from developing spliceâ€switching antisense therapies. EMBO Molecular Medicine, 2017, 9, 545-557.	3.3	119
9	How much dystrophin is enough: the physiological consequences of different levels of dystrophin in themdxmouse. Human Molecular Genetics, 2015, 24, 4225-4237.	1.4	116
10	A Comparative Study of Î±â€Dystroglycan Glycosylation in Dystroglycanopathies Suggests that the Hypoglycosylation of Î±â€Dystroglycan Does Not Consistently Correlate with Clinical Severity. Brain Pathology, 2009, 19, 596-611.	2.1	107
11	Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. Molecular Therapy - Nucleic Acids, 2012, 1, e27.	2.3	91
12	Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucleic Acids Research, 2013, 41, 9500-9513.	6.5	83
13	Mild POMGnT1 Mutations Underlie a Novel Limb-Girdle Muscular Dystrophy Variant. Archives of Neurology, 2008, 65, 137-41.	4.9	73
14	Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment. Nucleic Acid Therapeutics, 2019, 29, 1-12.	2.0	70
15	Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Scientific Reports, 2015, 5, 8986.	1.6	43
16	Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Human Molecular Genetics, 2015, 24, 6756-6768.	1.4	42
17	Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMD. Molecular Therapy - Nucleic Acids, 2018, 13, 1-15.	2.3	41
18	Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy. PLoS ONE, 2018, 13, e0198897.	1.1	19

#	Article	IF	Citations
19	Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy. Scientific Reports, 2015, 5, 11632.	1.6	12
20	Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. Human Molecular Genetics, 2019, 28, 396-406.	1.4	10
21	Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides. Molecular Therapy - Nucleic Acids, 2014, 3, e212.	2.3	8
22	Exclusion of WWP1 mutations in a cohort of dystroglycanopathy patients. Muscle and Nerve, 2011, 44, 388-392.	1.0	4